Full article at my site #HealthNews #FDA #PatientSafety #HeartHealth #Pharmacy To view or add a comment, sign in FDA accepts license application for a treatment of generalised pustular psoriasis The US Food and Drug Administration (FDA) has accepted the filing of a Biologics License Application (BLA) for imsidolimab for the treatment of generalised pustular psoriasis (GPP), with a target action date of 12 December 2026
Be sure to check the ingredients and nutritional values on the packaging if youre curious about what makes a product GLP-1-friendly. Positioning your food brand in the Ozempic era The rise of medications like Ozempic, Mounjaro and Wegovy is fundamentally changing how consumers relate to food
Dietary changes eating smaller meals, avoiding high-fat and spicy foods, staying hydrated reduce nausea substantially
People experiencing fatigue: B12 plays a role in energy production, and supplementation may help alleviate fatigue
Current Safety Evidence and Clinical Trial Data Known Side Effects and Risks to Be Aware Of Who Should Avoid Retatrutide or Use It With Caution Retatrutide's Regulatory Status in the UK Speaking to Your GP or Specialist Before Starting Treatment Scientific References Frequently Asked Questions What Is Retatrutide and How Does It Work
Biological Activity 2 O